KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Retained Earnings (2016 - 2025)

Historic Retained Earnings for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$1.8 billion.

  • CRISPR Therapeutics AG's Retained Earnings fell 3675.16% to -$1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 billion, marking a year-over-year decrease of 3675.16%. This contributed to the annual value of -$1.4 billion for FY2024, which is 3663.62% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Retained Earnings stood at -$1.8 billion, which was down 3675.16% from -$1.7 billion recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Retained Earnings registered a high of $72.5 million during Q2 2021, and its lowest value of -$1.8 billion during Q3 2025.
  • In the last 5 years, CRISPR Therapeutics AG's Retained Earnings had a median value of -$976.9 million in 2023 and averaged -$917.4 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Retained Earnings skyrocketed by 11937.62% in 2021, and later plummeted by 124544.61% in 2022.
  • CRISPR Therapeutics AG's Retained Earnings (Quarter) stood at -$195.9 million in 2021, then plummeted by 331.87% to -$846.1 million in 2022, then dropped by 18.16% to -$999.7 million in 2023, then crashed by 36.64% to -$1.4 billion in 2024, then plummeted by 33.02% to -$1.8 billion in 2025.
  • Its Retained Earnings was -$1.8 billion in Q3 2025, compared to -$1.7 billion in Q2 2025 and -$1.5 billion in Q1 2025.